{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T18:10:05Z","timestamp":1744049405490,"version":"3.40.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,3,20]],"date-time":"2004-03-20T00:00:00Z","timestamp":1079740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2004,3,20]],"date-time":"2004-03-20T00:00:00Z","timestamp":1079740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s10067-004-0864-0","type":"journal-article","created":{"date-parts":[[2004,3,19]],"date-time":"2004-03-19T15:49:39Z","timestamp":1079711379000},"page":"256-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation"],"prefix":"10.1007","volume":"23","author":[{"given":"W.","family":"Miesbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Scharrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A.","family":"Asherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,3,20]]},"reference":[{"key":"864_CR1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"Wilson","year":"1999","unstructured":"Wilson WA, Gharavi AE, Koike T et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309\u20131311","journal-title":"Arthritis Rheum"},{"key":"864_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S1471-4906(02)00007-8","volume":"24","author":"Shoenfeld","year":"2003","unstructured":"Shoenfeld Y (2003) Etiology and pathogenic mechanism of the anti-phospholipid syndrome unraveled. Trends Immunol 24:2\u20134","journal-title":"Trends Immunol"},{"key":"864_CR3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/096120339800700226","volume":"8","author":"Roubey","year":"1998","unstructured":"Roubey RAS (1998) Mechanism of autoantibody-mediated thrombosis. Lupus 8:114\u201320 (suppl 2)","journal-title":"Lupus"},{"key":"864_CR4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","volume":"346","author":"Levine","year":"2002","unstructured":"Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346:752\u2013763","journal-title":"N Engl J Med"},{"key":"864_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1006\/jaut.2000.0409","volume":"15","author":"Petri","year":"2000","unstructured":"Petri M (2000) Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 15:145\u2013151","journal-title":"J Autoimmun"},{"key":"864_CR6","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"Cervera","year":"2002","unstructured":"Cervera R, Piette JC, Font J et al. (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019\u20131027","journal-title":"Arthritis Rheum"},{"key":"864_CR7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1055\/s-0038-1649901","volume":"74","author":"Brandt","year":"1995","unstructured":"Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74:1185\u20131190","journal-title":"Thromb Haemost"},{"key":"864_CR8","doi-asserted-by":"crossref","unstructured":"Mackie IJ, Donohoe S, Machin SJ (2000) Lupus anticoagulant measurement. In: Khamashta MA (ed) Hughes syndrome. Antiphospholipid syndrome. Springer, London, pp 214\u2013225","DOI":"10.1007\/978-1-4471-3666-8_22"},{"key":"864_CR9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1055\/s-0038-1649701","volume":"70","author":"Triplett","year":"1993","unstructured":"Triplett DA, Stocker KF, Unger GA (1993) The Textarin\/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 70:925\u2013931","journal-title":"Thromb Haemost"},{"key":"864_CR10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V68.4.869.869","volume":"68","author":"Thiagarajan","year":"1986","unstructured":"Thiagarajan P, Pengo V, Shapiro SS (1986) The use of the dilute Russell viper venome time for the diagnosis of lupus anticoagulants. Blood 68:869\u2013874","journal-title":"Blood"},{"key":"864_CR11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/s-0038-1651083","volume":"57","author":"Rosner","year":"1987","unstructured":"Rosner E, Pauzner R, Lusky A, Modan M, Many A (1987) Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 57:144\u2013147","journal-title":"Thromb Haemost"},{"key":"864_CR12","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(83)91267-9","volume":"2","author":"Harris","year":"1983","unstructured":"Harris EN, Gharavi AE, Boey ML et al. (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2:1211\u20131214","journal-title":"Lancet"},{"key":"864_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/00001721-200306000-00011","volume":"14","author":"Koschmieder","year":"2003","unstructured":"Koschmieder S, Miesbach W, Fauth F, Bojunga J, Scharrer I, Brodt HR (2003) Combined plasmapharesis and immunosuppression as rescue treatment of a patient with catastrophic antiphospholipid syndrome occurring despite anticoagulation: a case report. Blood Coag Fibrinol 14:395\u2013399","journal-title":"Blood Coag Fibrinol"},{"key":"864_CR14","doi-asserted-by":"crossref","unstructured":"Asherson RA, Cervera R, Piette JC et al. (1998) Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77:195\u2013207","DOI":"10.1097\/00005792-199805000-00005"},{"key":"864_CR15","first-page":"508","volume":"19","author":"Asherson","year":"1992","unstructured":"Asherson RA (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19:508\u2013512","journal-title":"J Rheumatol"},{"key":"864_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/1096-8652(200010)65:2<154::AID-AJH11>3.0.CO;2-A","volume":"65","author":"Triplett","year":"2000","unstructured":"Triplett DA, Asherson RA (2000) Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Haematol 65:154\u2013159","journal-title":"Am J Haematol"},{"key":"864_CR17","first-page":"196","volume":"154","author":"Piette","year":"2003","unstructured":"Piette JC, Cervera R, Levy RA, Nasonov EL, Triplett DA, Shoenfeld Y (2003) The catastrophic antiphospholipid syndrome \u2013 Asherson\u2019s syndrome. Ann Med Interne 154:196\u2013196","journal-title":"Ann Med Interne"},{"key":"864_CR18","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1161\/01.STR.28.9.1660","volume":"28","author":"Levine","year":"1997","unstructured":"Levine SR, Salowich-Palm L, Sawaya KL et al. (1997) IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28:1660\u20131665","journal-title":"Stroke"},{"key":"864_CR19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","volume":"117","author":"Rosove","year":"1992","unstructured":"Rosove MH, Brewer PMC (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117:303\u2013308","journal-title":"Ann Intern Med"},{"key":"864_CR20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/ard.52.9.689","volume":"52","author":"Derksen","year":"1993","unstructured":"Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK (1993) Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 52:689\u2013692","journal-title":"Ann Rheum Dis"},{"key":"864_CR21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","volume":"332","author":"Khamashta","year":"1995","unstructured":"Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993\u2013997","journal-title":"N Engl J Med"},{"key":"864_CR22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJM200104193441607","volume":"344","author":"Seligsohn","year":"2001","unstructured":"Seligsohn U, Lubetsky A (2001) Genetic susceptibility to venous thrombosis. N Engl J Med 344:1222\u20131231","journal-title":"N Engl J Med"},{"key":"864_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1046\/j.1365-2141.2001.02981.x","volume":"114","author":"Walker","year":"2001","unstructured":"Walker ID, Greaves M, Preston FE (2001) Investigation and management of heritable thrombophilia. Br J Haematol 114:512\u2013528","journal-title":"Br J Haematol"},{"key":"864_CR24","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood.V86.10.3685.bloodjournal86103685","volume":"86","author":"Ginsberg","year":"1995","unstructured":"Ginsberg JS, Wells PS, Brill-Edwards P et al. (1995) Antiphospholipid antibodies and venous thromboembolism. Blood 86:3685\u20133691","journal-title":"Blood"},{"key":"864_CR25","first-page":"559","volume":"11","author":"Levine","year":"2002","unstructured":"Levine SR, Brey RL, Tilles BC, the APASS Study Group et al (2002) aPL and Stroke Study (APASS). Lupus 11:559 [Abstract]","journal-title":"Lupus"},{"key":"864_CR26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","volume":"42","author":"The","year":"1997","unstructured":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group (1997) A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42:857\u2013865","journal-title":"Ann Neurol"},{"key":"864_CR27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","volume":"314","author":"Rai","year":"1997","unstructured":"Rai R, Cohen H, Dave M, Regan L (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. Br Med J 314:253\u2013257","journal-title":"Br Med J"},{"key":"864_CR28","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0002-9378(96)70610-5","volume":"174","author":"Kutteh","year":"1996","unstructured":"Kutteh WH (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174:1584\u20131589","journal-title":"Am J Obstet Gynecol"},{"key":"864_CR29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/096120330000900717","volume":"9","author":"Malaviya","year":"2000","unstructured":"Malaviya AN, Mourou M (2000) Should low-dose aspirin also be a background therapy for all patients with systemic lupus erythematosus (SLE)? Lupus 9:561\u2013562","journal-title":"Lupus"},{"key":"864_CR30","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1001\/archinte.160.13.2042","volume":"160","author":"Wahl","year":"2000","unstructured":"Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP (2000) Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 160:2042\u20132048","journal-title":"Arch Intern Med"},{"key":"864_CR31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1191\/0961203303lu388oa","volume":"12","author":"Alarc\u00f3n-Segovia","year":"2003","unstructured":"Alarc\u00f3n-Segovia D, Boffa MC, Branch W et al. (2003) Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12:499\u2013503","journal-title":"Lupus"},{"key":"864_CR32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1191\/0961203303lu389oa","volume":"12","author":"Meroni","year":"2003","unstructured":"Meroni PL, Moia M, Derksen RHWM et al. (2003) Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus 12:504\u2013507","journal-title":"Lupus"},{"key":"864_CR33","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1191\/0961203303lu390oa","volume":"12","author":"Brey","year":"2003","unstructured":"Brey RL, Chapman J, Levine SR et al. (2003) Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 12:508\u2013513","journal-title":"Lupus"},{"key":"864_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1191\/0961203303lu392oa","volume":"12","author":"Chapman","year":"2003","unstructured":"Chapman J, Rand JH, Brey RL et al. (2003) Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 12:514\u2013517","journal-title":"Lupus"},{"key":"864_CR35","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1191\/0961203303lu391oa","volume":"12","author":"Lockshin","year":"2003","unstructured":"Lockshin M, Tenedios F, Petri M et al. (2003) Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 12:518\u2013523","journal-title":"Lupus"},{"key":"864_CR36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1191\/0961203303lu393oa","volume":"12","author":"Tincani","year":"2003","unstructured":"Tincani A, Branch W, Levy RA et al. (2003) Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12:524\u2013529","journal-title":"Lupus"},{"key":"864_CR37","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1191\/0961203303lu394oa","volume":"12","author":"Asherson","year":"2003","unstructured":"Asherson RA, Cervera R, de Groot PG et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530\u2013534","journal-title":"Lupus"},{"key":"864_CR38","first-page":"12","volume":"27","author":"Asherson","year":"2000","unstructured":"Asherson RA, Shoenfeld Y (2000) The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome -- molecular mimicry? J Rheumatol 27:12\u201314","journal-title":"J Rheumatol"},{"key":"864_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/(SICI)1098-1101(1999)14:4<171::AID-JCA3>3.0.CO;2-5","volume":"14","author":"Flamholz","year":"1999","unstructured":"Flamholz R, Tran T, Grad GI et al. (1999) Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta (2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apheresis 14:171\u2013176","journal-title":"J Clin Apheresis"},{"key":"864_CR40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-127-3-199708010-00001","volume":"127","author":"Moll","year":"1997","unstructured":"Moll S, Ortel TL (1997) Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 127:177\u2013185","journal-title":"Ann Intern Med"},{"key":"864_CR41","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood.V61.4.684.684","volume":"61","author":"Bajaj","year":"1983","unstructured":"Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB (1983) A mechanism for the hypoprothrombinemia of the acquired hypoprothtrombinemia-lupus anticoagulant syndrome. Blood 61:684\u2013692","journal-title":"Blood"},{"key":"864_CR42","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.1780400823","volume":"40","author":"Neuwelt","year":"1997","unstructured":"Neuwelt CM, Daikh DI, Linfoot JA et al. (1997) Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years. Arthritis Rheum 40:1534\u20131539","journal-title":"Arthritis Rheum"},{"key":"864_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1191\/0961203302lu178oa","volume":"11","author":"Erkan","year":"2002","unstructured":"Erkan D, Zhang HW, Shriky RC, Merrill JT (2002) Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 11:215\u2013220","journal-title":"Lupus"},{"key":"864_CR44","first-page":"1716","volume":"24","author":"Al","year":"1997","unstructured":"Al Sayegh FA, Ensworth S, Huang S, Stein HB, Klinkhoff AV (1997) Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. J Rheumatol 24:1716\u20131718","journal-title":"J Rheumatol"},{"key":"864_CR45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1191\/0961203303lu396xx","volume":"12","author":"Shoenfeld","year":"2003","unstructured":"Shoenfeld Y (2003) Systemic antiphospholipid syndrome. Lupus 12: 497\u2013498","journal-title":"Lupus"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-004-0864-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-004-0864-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-004-0864-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-004-0864-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T17:45:07Z","timestamp":1744047907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-004-0864-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,20]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s10067-004-0864-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2004,3,20]]},"assertion":[{"value":"2 October 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}